摘要
众所周知,心血管疾病是2型糖尿病患者发病和死亡的主要原因。在过去的几年里,讨论最多的话题之一是抗糖尿病药物的CV安全性。关于老年抗糖尿病药物的CV安全性,数据不太清楚,关于其CV安全性的结论主要是基于旨在评估其降糖效果的随机对照试验。在这篇综述中,我们总结了当前有关旧的和新的抗糖尿病药物的CV安全性的知识。根据已发表的文献,二甲双胍是治疗2型糖尿病的第一种药物,似乎具有心脏保护作用。当二甲双胍单药不能达到HbA1c靶点时,第二线药物的选择就不那么清楚了。根据EMPA-Reg结果试验的发现和最近发表的6项试验的领导者和持续6项试验,表观利氟嗪、利拉格鲁帝和半谷胱甘肽作为CV病患者的二线药物似乎是合理的选择。另一方面,磺脲类药物,除格列齐特外,应在这些患者中加以避免,尽管目前尚缺乏CV安全性试验。在没有CV疾病的个体中,任何其他类型的抗糖尿病药物都可以通过以病人为中心的方法来选择。Saxagliptin、alogliptin、sitagliptin和Lixisenatide已在CV安全性试验中得到评价,并对CV结果产生中性影响,而吡格列酮可能具有一定的CV效果。然而,在心力衰竭患者中应避免使用沙司他汀和阿霉素,而吡格列酮在这一人群中是违禁的。
关键词: 心血管事件,二甲双胍,磺脲,吡格列酮,胰岛素,二肽酰肽酶-4抑制剂,胰高血糖素样肽-1受体激动剂,钠-葡萄糖共转运蛋白-2抑制剂。
Current Medicinal Chemistry
Title:Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications
Volume: 25 Issue: 13
关键词: 心血管事件,二甲双胍,磺脲,吡格列酮,胰岛素,二肽酰肽酶-4抑制剂,胰高血糖素样肽-1受体激动剂,钠-葡萄糖共转运蛋白-2抑制剂。
摘要: It is known that Cardiovascular (CV) disease is the leading cause of morbidity and mortality in individuals with type 2 diabetes. Over the last years, one of the most discussed topics is the CV safety of anti-diabetic medications. Regarding CV safety of older antidiabetic agents the data are less clear and conclusions about their CV safety are mostly based on randomized controlled trials designed to assess their glucose lowering efficacy. In this review, we summarize the current knowledge about the CV safety of older and newer antidiabetic medications.
According to the published literature metformin is the first line agent for the treatment of type 2 diabetes and seems to have cardio-protective effects. The choice of the second line agent when metformin monotherapy fails to achieve HbA1c targets is less clear. In the light of the findings of the EMPA-REG OUTCOME trial and the recently published LEADER and SUSTAIN 6 trials, empagliflozin, liraglutide and semaglutide seem reasonable options as second line agents for patients with CV disease. Sulfonylureas on the other hand, with the exception of gliclazide, should be avoided in those patients, although CV safety trials are still lacking. In individuals without CV disease any of the other classes of anti-diabetic medication can be selected on a patient-centered approach. Saxagliptin, alogliptin, sitagliptin and lixisenatide have been evaluated in CV safety trials and have neutral effects on CV outcomes, while pioglitazone may have some CV benefits. Saxagliptin and alogliptin, however, should be avoided in patients with heart failure, while pioglitazone is contraindicated in this population.
Export Options
About this article
Cite this article as:
Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications, Current Medicinal Chemistry 2018; 25 (13) . https://dx.doi.org/10.2174/0929867324666170530075533
DOI https://dx.doi.org/10.2174/0929867324666170530075533 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Current Drug Metabolism Targeting Heme Oxygenase-1 in Vascular Disease
Current Drug Targets New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Preface: Facing New Challenges in Cardiovascular Disease, When the Pressure Goes Up and the Pump Goes Astray
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Role of Redox Homeostasis and Inflammation in the Pathogenesis of Pulmonary Arterial Hypertension
Current Medicinal Chemistry Crude Venom from Nematocysts of the Jellyfish Pelagia noctiluca as a Tool to Study Cell Physiology
Central Nervous System Agents in Medicinal Chemistry Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications
Mini-Reviews in Medicinal Chemistry Rheumatological Diseases in HIV Infection
Current Rheumatology Reviews Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine The Effects of Statin Therapy on the Human Airway
Drug Metabolism Letters Hypercoagulability and Nephrotic Syndrome
Current Vascular Pharmacology Replicative Senescence: The Final Stage of Memory T Cell Differentiation?
Current HIV Research Pharmacological Inhibition of Platelet Reactivity. Clinical and Pharmacodynamic Effects
Current Vascular Pharmacology Editorial: The Interplay between TSH and Lipids. What Should Clinicians Know?
Current Vascular Pharmacology Elevated Heart Rate, A Risk Factor and Risk Marker of Cardiovascular Disease
Current Hypertension Reviews Myostatin Inhibition and Cardiometabolic Disorders
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The VHL Tumor Suppressor: Master Regulator of HIF
Current Pharmaceutical Design G Protein-Coupled Receptor Fusion Proteins in Drug Discovery
Current Pharmaceutical Design Editorial [Hot Topic:Anabolic Androgenic Steroids (AAS) as Doping Agents: Chemical Structures,Metabolism, Cellular Responses, Physiological and Pathological Effects (Guest Editor: V. Fineschi)]
Mini-Reviews in Medicinal Chemistry Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry